Expert Review of Pharmacoeconomics and Outcomes Research

Aims & Scope

Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches.

Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.

All articles are subject to rigorous peer-review.

The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.5
2024	1.80

SJR (SCImago Journal Rank)

Year	Value
2024	0.585

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	66

Journal Rank

Year	Value
2024	9920

Journal Citation Indicator

Year	Value
2024	655

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost–effectiveness

  Citation: 565

  Authors: Erik, Brjánn, Nils

• KIDSCREEN-52 quality-of-life measure for children and adolescents

  Citation: 557

  Authors: Ulrike, Angela, Luis, Michael, Jeanet, Wolfgang, Pascal, Mick, Thomas, Ladislav, Joanna, Agnes, Yannis, Curt, Jean, European

• A point of minimal important difference (MID): a critique of terminology and methods

  Citation: 523

  Authors: Madeleine T

• Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

  Citation: 520

  Authors: Scott D

• The truly remarkable universality of half a standard deviation: confirmation through another look

  Citation: 405

  Authors: Geoffrey R, Jeff A, Kathleen W

• Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research

  Citation: 372

  Authors: Cicely, Annabel, Diane

• Impact of multidrug-resistant<i>Pseudomonas aeruginosa</i>infection on patient outcomes

  Citation: 319

  Authors: Elizabeth B, Vincent H

• Economic burden of healthcare-associated infections: an American perspective

  Citation: 296

  Authors: Patricia W

• The PedsQLâ„¢ as a pediatric patient-reported outcome: reliability and validity of the PedsQLâ„¢ Measurement Model in 25,000 children

  Citation: 269

  Authors: James W, Tasha M, Michael

• Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

  Citation: 263

  Authors: Boudewijn J.H., Thys, Bertine M. J., Antonella, Maarten J., Janwillem W.H., Job F.M.

---